Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30864379 | 0.81 | MTOR (0.42) | ALDH1A1SMN1; SMN2NISCHMTORADK | |
| SCHEMBL2947883 | 0.80 | — | — | |
| SCHEMBL3193203 | 0.80 | — | — | |
| SCHEMBL4685982 | 0.75 | — | — | |
| SCHEMBL12854154 | 0.75 | — | — | |
| SCHEMBL17368397 | 0.75 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2NISCHTAAR1 | |
| SCHEMBL22024413 | 0.75 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2NISCH | |
| SCHEMBL4685983 | 0.75 | — | — | |
| SCHEMBL4685300 | 0.73 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2TAAR1 | |
| SCHEMBL4684827 | 0.72 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184644-A | Polyol carbonate disulfate compound and preparation method thereof | 联化科技(临海)有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-116813518-A | Synthesis method of nemaltevir chiral intermediate | 江苏暨明医药科技有限公司 | 2023-09-29 | — | — | CN | claimed |
| EP-2736909-B1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | FARMA GRS D O O (SI) | 2017-03-29 | — | — | EP | claimed |
| EP-3109244-A2 | PREPARATION OF 2'FLUORO-2'-ALKYL-SUBSTITUTED OR OTHER OPTIONALLY SUBSTITUTED RIBOFURANOSYL PYRIMIDINES AND PURINES AND THEIR DERIVATIVES | Gilead Pharmasset LLC (US) | 2016-12-28 | — | — | EP | claimed |
| US-20150218126-A1 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION | GENERICS [UK] LIMITED (GB) | 2015-08-06 | — | — | US | claimed |
| EP-2121679-B1 | METHOD FOR PRODUCING AZONIASPIRONORTROPINE ESTERS | K H S PHARMA HOLDING GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| EP-2736909-A1 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | Farma GRS, d.o.o. (SI) | 2014-06-04 | — | — | EP | claimed |
| EP-2079691-B1 | SUBSTITUTED INDENO[1,2-B]INDOLE DERIVATIVES AS NOVEL INHIBITORS OF PROTEIN KINASE CK2 AND THEIR USE AS TUMOUR THERAPEUTIC AGENTS, CYTOSTATICS AND DIAGNOSTIC AIDS | UNIV DUESSELDORF H HEINE (DE) | 2013-08-14 | — | — | EP | claimed |
| US-20130143923-A1 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION | GENERICS [UK] LIMITED (GB) | 2013-06-06 | — | — | US | claimed |
| CN-103068812-A | Crystalline forms of thalidomide and processes for their preparation | GENERICS UK LTD | 2013-04-24 | — | — | CN | claimed |
| US-20050272934-A1 | Process for the synthesis of thalidomide | ANTIBIOTICOS S.P.A. (IT) | 2005-12-08 | — | — | US | claimed |
| EP-1602654-A1 | Process for the synthesis of thalidomide | Antibioticos S.p.A. (IT) | 2005-12-07 | — | — | EP | claimed |
| EP-0719280-B1 | PROCESS FOR THE PREPARATION OF COMPOUNDS HAVING ACE INHIBITORY ACTION AS WELL AS NOVEL COMPOUNDS USEFUL AS STARTING MATERIALS OR INTERMEDIATES IN SAID PROCESS | LEK TOVARNA FARMACEVTSKIH (SI) | 1999-11-10 | — | — | EP | claimed |
| US-5789597-A | ANGIOTENSIN CONVERTING ENZYME, ENALAPRIL MALEATE | LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, D.D. (SI) | 1998-08-04 | — | — | US | claimed |
| EP-0719280-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS HAVING ACE INHIBITORY ACTION AS WELL AS NOVEL COMPOUNDS USEFUL AS STARTING MATERIALS OR INTERMEDIATES IN SAID PROCESS | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. (SI) | 1996-07-03 | — | — | EP | claimed |
| WO-1996002564-A1 | PROCESS FOR THE PREPARATION OF COMPOUNDS HAVING ACE INHIBITORY ACTION AS WELL AS NOVEL COMPOUNDS USEFUL AS STARTING MATERIALS OR INTERMEDIATES IN SAID PROCESS | LEK, TOVARNA FARMACEVTSKIH IN KEMICNIH IZDELKOV, D.D. (SI) | 1996-02-01 | — | — | WO | claimed |
| EP-0257171-B1 | (BENZOFURAN-2-YL)IMIDAZOLES HAVING PHARMACEUTICAL ACTIVITY, THEIR SALTS AND RELEVANT PRODUCTION PROCESSES | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1990-08-29 | — | — | EP | claimed |
| EP-0257171-A1 | (Benzofuran-2-yl)imidazoles having pharmaceutical activity, their salts and relevant production processes | A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L. (IT) | 1988-03-02 | — | — | EP | claimed |
| EP-0226320-A1 | Imidazolyl thieno-benzothiepin derivatives and processes for the preparation thereof | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu (CS) | 1987-06-24 | — | — | EP | claimed |
| US-4342754-A | AND USE AS DIURETICS | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1982-08-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143923-A1 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION | TNF, UACA, VEGFA | ALDH1A1 2821/4885SMN1; SMN2 4318/4885NISCH 1934/4885 |
| US-20150218126-A1 | CRYSTALLINE FORMS OF THALIDOMIDE AND PROCESSES FOR THEIR PREPARATION | TNF, UACA, VEGFA | ALDH1A1 2821/4885SMN1; SMN2 4318/4885NISCH 1934/4885 |
| US-20050272934-A1 | Process for the synthesis of thalidomide | QPCT, GLUL, QPCTL | ALDH1A1 2027/4885SMN1; SMN2 3534/4885NISCH 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.